Mindmaze Therapeutics Holdin
Mindmaze Therapeutics Holdin (MMTX.SW) closed the trading session on Wednesday 21 April 2026 at 01:35 AM Central Europe with a decline of 5.8 %. The share price was approximately CHF 0.15 at the time of reporting.
- Shares outstanding: 170 million
- Market capitalization: CHF 24.3 million
- Trading volume (last 24 hours): CHF 82.4 k
- Change since the end of the previous month: +0.14 %
The 200‑day simple moving average is CHF 0.45. The all‑time high for the past 52 weeks was CHF 3.42 (29 October 2025) and the 52‑week low was CHF 0.13 (7 October 2026).
Recent performance of related stocks (last 24 hours)
| Ticker | Change | Current price | Market cap | Additional note |
|---|---|---|---|---|
| STRN.SW (Schlatter Industries) | +0.96 % | CHF 21 | CHF 23 million | P/E = 66.22 |
| ASWN.SW (Asmallworld) | +7.07 % | CHF 1.04 | CHF 15.2 million | — |
| EVE.SW (Evonext) | –2.05 % | CHF 2.30 | CHF 17.3 million | — |
| K2G.VI (K2g) | +0.82 % | EUR 1.23 | EUR 12.6 million | — |
| NCEL (Newcelx) | +5.20 % | USD 2.61 | USD 15.2 million | — |
Company overview
Mindmaze Therapeutics Holdin, operating as Relief Therapeutics Holding AG, is a commercial‑stage biopharmaceutical company. Its focus is on the identification, development, and commercialization of therapies for rare metabolic disorders, rare pulmonary diseases, and rare connective tissue disorders. The company is headquartered in Geneva, Switzerland, and its shares are listed on the SIX Swiss Exchange. For additional details about the company’s products, pipeline, and corporate information, visit the official website at www.relieftherapeutics.com .